This strong data reinforces the potential of the Shield test to detect multiple cancers earlier through a simple blood draw,” said AmirAli Talasaz, Guardant Health co-founder and co-CEO.

AmirAli Talasaz and Helmy Eltoukhy aim to offer a more appealing screening option. Their company, Guardant Health, co-founded ...

AmirAli Talasaz, co-founder and co-CEO of Guardant Health, expressed optimism about the Shield test’s potential to detect multiple cancers earlier through a simple blood draw, which could help reduce ...

Today TIME named to its 2025 TIME100 Health list co-CEOs Helmy Eltoukhy and AmirAli Talasaz of Guardant Health, Inc. (Nasdaq: ...

The American Cancer Society recommends that people at average risk of colorectal cancer start regular screening at age 45, and several blood tests on the market could help. These tests are done in ...

Guardant Health, Inc. is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, presented data today from a study showing that its ...

“It is a recognition of the incredible technology that our Guardant team has built with the Shield blood test for colorectal cancer and Shield’s ability to save lives around the worl ...

Guardant Health, Inc. (Nasdaq ... Results of the study served as the basis for the selection of the blood-based Shield MCD test by the National Cancer Institute (NCI) for inclusion in its upcoming ...